Open AccessPB2154 TIME TO FIRST PLATEAU AS A PROGNOSTIC PREDICTOR IN MULTIPLE MYELOMA
Author(s) -
Kirkizlar O.,
Umit E.,
Baysal M.,
Bas V.,
Gulsaran S.,
Demirci U.,
Demir A. M.
Publication year - 2019
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000567100.78591.c2
Subject(s) - medicine , multiple myeloma , bortezomib , cyclophosphamide , autologous stem cell transplantation , retrospective cohort study , surgery , gastroenterology , chemotherapy
Background: As novel treatments emerge, prognostic assessment has become the backbone of patients with multiple myeloma (MM). Depth and duration of response have been associated with survival and recently, evaluation residual disease status has been related with both progression free and overall survival. Aims: We aimed investigated the relation with time to plateau, which has been proposed by MayoClinic with survival in our patient group. Methods Data of 105 patients with MM, diagnosed and treated at our clinic between 2015 and 2018 were enrolled in a retrospective manner. All patients received bortezomib‐cyclophosphamide and dexametazone as first line therapy. Time to plateau was defined as best response date to the first line therapy. Results: Mean age was 65,86 years (28‐93). 49 patients were female (46,7%) while 56 were male (53,3). 29 patients had IgA disease while 74 were Ig G and 2 were light chain MM. 68 patients had International Scoring System (ISS) III disease (64,8%) while 27 had ISS II (25,7%) and 10 had ISS I disease (9,5%). Mean time to plateau was 6,74 months (4‐15) while mean overall survival was 44,87 months (8‐145). As all patients who were physically fit and <70 years of age have moved to autologous stem cell transplantation, we could not evaluate a duration of initial response. Patients who required less than 6 months (65 patients) to reach a plateau status had a mean survival of 47,51 months while patients requiring 6‐12 months had 41.23 months and patients who needed more than 12 months had a mean survival of 36 months. Summary/Conclusion: Despite the observation of MayoClinic, we did not observe a relation with slow responders and prolonged survival. On the contrary, we observed that patients who respond to first line therapy had a longer survival, probably related with more chemosensitive disease.